ライフサイエンスコーパス: bother

1 of treatment" was used to define side-effect bother.

2 ted odds and trajectories for odds of sexual bother.

3 cored as either no difficulty or very rarely bothered (0) to complete difficulty or very frequently b

4 anxiety, 3.33; 95% CI, 0.90-12.30; tinnitus bother, 12.08; 95% CI, 1.48-98.35).

5 bother (33.5% vs 16.0%, P = .001), swelling bother (29.6% vs 15.7%, P = .03), and fatigue (29.7% vs

6 n/always, 38.7% vs 15.7%, P = .002), hurting bother (33.5% vs 16.0%, P = .001), swelling bother (29.6

7 d 29.6% of female candidates reported sexual bother; 39.0% and 34.5%, respectively, had been sexually

8 0) to complete difficulty or very frequently bothered (4) with a total instrument score range of 0 to

9 and 27.0% female recipients reported sexual bother; 41.6% and 41.8%, respectively, had been sexually

10 ractive Bladder Questionnaire SF for symptom bother (-46.7 vs -38.6; mean difference, 8.1; 95% CI, 3.

11 ty of the patients stated that they were not bothered about having to take their medications (70.6%);

12 ndings of this study show that assessment of bother and anxiety levels in patients with tinnitus may

13 system for response to CBT based on tinnitus bother and anxiety levels.

14 dpoint of the QoL substudy was overall bowel bother and comparisons between fractionation groups were

15 ortant contributors to treatment side-effect bother and discontinuation.

16 sure of ejaculatory time although increasing bother and distress require assessment and establishment

17 uestionnaires measuring symptom distress and bother and health-related quality of life.

18 reased odds of increased patient side-effect bother and treatment discontinuation, with symptomatic A

19 f G1 and G2 AE counts on patient side-effect bother and treatment discontinuation.

20 of AEs experienced with patient side-effect bother and treatment discontinuation.

21 ve improved evaluation of men with BPH, yet 'bother' and 'health-related quality of life' should be b

22 rated bladder condition of at least moderate bother, and a bladder diary documenting micturition freq

23 lthough both sexual and urinary function and bother are associated with quality of life, men who are

24 city (SCIN), regarding the extent of symptom bother as 0, "not at all"; 1, "a little"; 2, "quite a bi

25 ere found in quality of life, wrist pain, or bother at 3 and 12 months.

26 however, less than 5% of patients were very bothered at month 6.

27 due to end-stage kidney disease (ie, sexual bother) at KT evaluation, admission, and post-KT follow-

28 increased self-reported patient side-effect bother by 13% (95% CrI, 1.06 to 1.21) and 35% (95% CrI,

29 0.7-23.3]; P = .047) and reported being less bothered by adverse effects (mean [SD], 3.0 [0.9] in the

30 atigue, and the extent to which patients are bothered by dermatitis in patients with breast cancer un

31 Vision (40 points, 95% CI 7-73, P = .02) and Bothered by Eyes/Vision (23 points, 95% CI 3-45, P = .02

32 3 questionnaires/domains: functional vision, bothered by eyes/vision, social (total 29 items).

33 pleted the Child PedEyeQ (functional vision, bothered by eyes/vision, social, and frustration/worry d

34 for the Child PedEyeQ are functional vision, bothered by eyes/vision, social, and frustration/worry.

35 l domains/questionnaires: functional vision, bothered by eyes/vision, social, frustration/worry (10 i

36 Proxy PedEyeQ domains are functional vision, bothered by eyes/vision, social, frustration/worry, and

37 5 questionnaires/domains: functional vision, bothered by eyes/vision, social, frustration/worry, eye

38 In addition, fatigued women were more bothered by menopausal symptoms and were somewhat more l

39 s of control for health outcomes and feeling bothered by part of the transplant experience were assoc

40 tcomes were controlled by chance and feeling bothered by part of the transplant experience were assoc

41 onfidence interval [CI], 1.1-1.7), not being bothered by scope insertion (OR 2.0; 95% CI, 1.2-3.3), b

42 d with excellent pain control were not being bothered by scope insertion (versus bothered, OR = 3.65

43 Assessment of Cancer Therapy-GP5 item, "I am bothered by side effects of treatment" was used to defin

44 were similar between arms, including being 'bothered by side-effects of treatment', except for diarr

45 er PHQ responses on symptom frequency, being bothered by symptoms, or both; and (3) how they would an

46 s, including breast pain, fatigue, and being bothered by symptoms.

47 Less than 5% of patients were very bothered by the photic visual disturbances associated wi

48 ted they were 'not at all' or 'a little bit' bothered by the side effects of cancer therapy across ti

49 iated with quality of life, men who are more bothered by their urination or impotence are more likely

50 For four exclusively emotional symptoms (bothered by things, hopelessness about the future, felt

51 eing "not at all," "a little," or "somewhat" bothered by treatment side-effects at each visit, as det

52 s and makes sense only for those who are not bothered by treatment.

53 roblems sleeping through the night; 34% were bothered by unrefreshing sleep; and 33% reported that th

54 stinguish patients who are not significantly bothered by vitreous floaters from those with clinically

55 f trouble breathing due to asthma, reporting bother caused by asthma, and/or limitation in activities

56 The estimated prevalence of sexual bother decreased during the first 3 years post-KT (odds

57 diversity, and perhaps more importantly, why bother finding out.

58 Frequent bother from at least one breast symptom was reported by

59 es (aged >=21 years) with moderate to severe bother from both stress and urgency urinary incontinence

60 D symptoms, patients reported moderate/major bother from fatigue (26%), joint pain (22%), and problem

61 higher total complement (p = 0.012), greater bother from foods or oral ulcers and greater mouth pain,

62 ristics associated with (1) breast pain, (2) bother from itching, stinging/burning, swelling, or hurt

63 s reported "not at all" or "a little bit" of bother from treatment side-effects.

64 For those with high adverse-effect bother, GP5 while undergoing treatment was associated wi

65 h," and "quite a bit") and low adverse event bother (ie, "somewhat," "a little bit," or "not at all")

66 nths) were categorized as high adverse event bother (ie, "very much," and "quite a bit") and low adve

67 26 (6%), 28 (7%), and 38 (9%) men; moderate bother in 19 (5%), 23 (6%), and 21 (5%) men, and severe

68 92 (22%), 91 (22%), and 93 (21%) men; small bother in 26 (6%), 28 (7%), and 38 (9%) men; moderate bo

69 ns groups at 2 years showed no overall bowel bother in 269 (66%), 266 (65%), and 282 (65%) men; very

70 %), 266 (65%), and 282 (65%) men; very small bother in 92 (22%), 91 (22%), and 93 (21%) men; small bo

71 9 (5%), 23 (6%), and 21 (5%) men, and severe bother in four (<1%), three (<1%) and three (<1%) men re

72 Sexual bother is common pre-KT and improves post-KT, and sexual

73 ondary outcomes included measures of urinary bother, nocturia, peak uroflow, postvoid residual volume

74 on the patient's perception of the impact or bother of asthma on his or her life.

75 41.1% vs 24.2%, P = .003), burning/stinging bother (often/always, 38.7% vs 15.7%, P = .002), hurting

76 ot being bothered by scope insertion (versus bothered, OR = 3.65 [95% CI, 1.99-6.98]), no memory of F

77 ve neuropathy subscale-related symptoms that bothered patients with CRC the most during the past week

78 Secondary outcomes were hot flash bother, recorded on daily diaries, and clinical improvem

79 ed reporting moderate or big sexual function bother (reported by 39.0%; OR, 2.77; 95% CI, 1.51 to 5.0

80 1.51 to 5.0), moderate or big bowel function bother (reported by 7.7%; OR, 2.32; 95% CI, 1.04 to 5.15

81 between treatment groups in change of bowel bother score from baseline or pre-radiotherapy to 24 mon

82 antigen, prostate volume, symptom score and bother score, decreased flow rate, and increased postvoi

83 C-26 urinary and bowel functional domains or bother scores.

84 was available (25.2%), they did not want to bother the pediatrician after hours (15.4%), or they tho

85 sking the respondents whether their symptoms bothered them enough to want another surgery, if the IOL

86 d (ie, the frequency with which the problems bothered them).

87 ever, questions remain as why microbes would bother to have different strategies of taking up nutrien

88 Symptom bother was assessed by O'Leary-Sant symptom scores (OSS)

89 Sexual function and bother were also independently associated with worse gen

90 o moderate anxiety level and severe tinnitus bother were associated with treatment response (adjusted

91 Urinary function and bother were independently associated with worse general

92 est that simple assessment of adverse-effect bother while receiving treatment is an efficient way to

93 nt-reported treatment success, patient-rated bother with appearance, and posttreatment complications.

94 cations, patient-reported treatment success, bother with appearance, and therapy use.

95 ifferent and you are so good at so much, why bother [with coaching]?" P009), worry about appearing in

96 c were associated with increased side-effect bother, with asymptomatic AEs showing no association reg

97 ch does having this symptom (or consequence) bother you?".